Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27182505 | 0.87 | F2RL1 (0.40) | MAPK1NPC1NOTUMF2RL1KDM4E | |
| SCHEMBL17068994 | 0.87 | HCRTR1 (0.40) | MAPK1NPC1NOTUMF2RL1KDM4E | |
| SCHEMBL27819863 | 0.87 | F2RL1 (0.47) | MAPK1NPC1NOTUMF2RL1KDM4E | |
| SCHEMBL5539875 | 0.82 | GRM5 (0.40) | MAPK1NPC1NOTUMF2RL1KDM4E | |
| SCHEMBL15238045 | 0.82 | LMNA (0.39) | MAPK1NPC1NOTUMF2RL1KDM4E | |
| SCHEMBL1586750 | 0.81 | HCRTR1 (0.47) | F2RL1LMNAJAK2TYK2HCRTR1 | |
| SCHEMBL5165206 | 0.81 | KDM4E (0.44) | MAPK1NPC1NOTUMF2RL1KDM4E | |
| SCHEMBL26981447 | 0.78 | KDM4E (0.41) | MAPK1NPC1NOTUMF2RL1KDM4E | |
| SCHEMBL12988403 | 0.78 | KDM4E (0.50) | MAPK1NOTUMF2RL1KDM4EALDH1A1 | |
| SCHEMBL17144712 | 0.78 | NOTUM (0.48) | MAPK1NOTUMF2RL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421834-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | claimed |
| CN-113226321-B | Pyrazolyl compounds and methods of use thereof | 阿利安制药有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-114773314-A | Biarylaminoguanidine derivative | 上海拓界生物医药科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-113226321-A | Pyrazolyl compounds and methods of use thereof | 阿利安制药有限责任公司 | 2021-08-06 | — | — | CN | disclosed |
| US-11053221-B2 | Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity | ARRIEN PHARMACEUTICALS LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053221-B2 | Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity | ARRIEN PHARMACEUTICALS LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200131154-A1 | PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | ARRIEN PHARMACEUTICALS LLC | 2020-04-30 | — | — | US | disclosed |
| US-20200131154-A1 | PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | ARRIEN PHARMACEUTICALS LLC | 2020-04-30 | — | — | US | disclosed |
| CN-109563048-A | Process for preparing 3-amino-1- (2, 6-disubstituted phenyl) pyrazoles | 拜耳农作物科学股份公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-103140490-A | Azaindazole compounds | BRISTOL MYERS SQUIBB CO | 2013-06-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053221-B2 | Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity | MELK, TK1, DCK | MAPK1 249/4885NPC1 4132/4885NOTUM 4671/4885 |
| US-20200131154-A1 | PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | PAICS, MCL1, TP53 | MAPK1 1826/4885NPC1 1806/4885NOTUM 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.